Olaparib Defers Progression of Serous Ovarian Cancer - Again
July 10, 2012|Ob.Gyn. News
Author and Disclosure Information
AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
During the maintenance phase of treatment, the overall rate of grade 3 or worse adverse events was 29% in the olaparib group and 16% in the control group, and "there were no additional safety concerns or safety signals that emerged related to toxicity of olaparib."
Dr. Oza disclosed that he receives research funding from AstraZeneca. Dr. Seiden disclosed no relevant conflicts of interest.
